Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499 | Director · Chief Executive Officer | June 18, 2026 | June 23, 2026 |
| Intellia Therapeutics, Inc.NTLA · Entity 4585 | Director | June 09, 2026 | June 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGIOS PHARMACEUTICALS, INC.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Performance share unitsSEC Table II · derivative / convertible security | Direct | 39,000 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Exercise / conversion · Disposed 39,000 · Balance 39,000 F1: Each performance stock unit represents a contingent right to receive one share of the issuer's common stock. F2: Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service. |
| Restricted stock unitsSEC Table II · derivative / convertible security | Direct | 39,000 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Grant · Acquired 39,000 · Balance 39,000 F3: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2: Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: Each performance stock unit represents a contingent right to receive one share of the issuer's common stock.
F2: Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service.
F3: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
Intellia Therapeutics, Inc.
Report date June 09, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,609 |
Reported balance
After 2026-06-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 9,200 · Balance 32,609 F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.89 · Expires 2036-06-08 | Direct | 13,300 |
Reported balance
After 2026-06-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-09 · Grant · Acquired 13,300 · Balance 13,300 F2: This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2: This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALEXION PHARMACEUTICALS, INC.
Report date July 21, 2021 · Filed July 23, 2021
Section 16 reporting ended · disclosed 2021-07-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.0001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-07-21 transaction · row 1
1 source rowRow 1 · 2021-07-21 · Disposition to issuer · Disposed 150,832 · Balance 0 F1: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration"). |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $100.14 · Expires 2027-06-07 | Direct | 0 |
Reported balance
After 2021-07-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-07-21 · Disposition to issuer · Disposed 21,750 · Balance 0 F2: Upon the First Effective Time, these options were cancelled and converted into the right to receive the product obtained by multiplying (A) the excess, if any, of the value of the Merger Consideration over the exercise price per share of the Alexion common stock subject to such options immediately prior to the First Effective Time by (B) the number of shares of Alexion common stock subject to such option immediately prior to the First Effective Time by (ii) the value of the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration").
F2: Upon the First Effective Time, these options were cancelled and converted into the right to receive the product obtained by multiplying (A) the excess, if any, of the value of the Merger Consideration over the exercise price per share of the Alexion common stock subject to such options immediately prior to the First Effective Time by (B) the number of shares of Alexion common stock subject to such option immediately prior to the First Effective Time by (ii) the value of the Merger Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 13, 2024 Filed Jun 17, 2024 21:14 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 15,409 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-074383 · ownership.xml · nonDerivative · entry 1 Goff Brian · CIK 0001546216 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,409 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:25 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionPerformance share units · Derivative | 25,527 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000073 · wk-form4_1717791913.xml · derivative · entry 3 Goff Brian · CIK 0001546216 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,583 Underlying: Common stock · 25,527 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The PSUs were granted on August 8, 2022. The PSUs vest as to 15% of the underlying shares upon the achievement of a specified clinical milestone and as to the remaining underlying shares upon the achievement of other clinical, research and regulatory milestones. The performance criteria for the specified clinical milestone was determined to have been met on June 5, 2024, resulting in the vesting of the PSUs as to 15% of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The PSUs were granted on August 8, 2022. The PSUs vest as to 15% of the underlying shares upon the achievement of a specified clinical milestone and as to the remaining underlying shares upon the achievement of other clinical, research and regulatory milestones. The performance criteria for the specified clinical milestone was determined to have been met on June 5, 2024, resulting in the vesting of the PSUs as to 15% of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:25 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 12,115 | $48.84 | $591,696.60 |
DisclosureSEC source: 0001439222-24-000073 · wk-form4_1717791913.xml · nonDerivative · entry 2 Goff Brian · CIK 0001546216 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,192 F1 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated August 8, 2022. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:25 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 25,527 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000073 · wk-form4_1717791913.xml · nonDerivative · entry 1 Goff Brian · CIK 0001546216 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,307 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2024 Filed Mar 5, 2024 21:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 4,156 | $32.57 | $135,360.92 |
DisclosureSEC source: 0001439222-24-000048 · wk-form4_1709673014.xml · nonDerivative · entry 2 Goff Brian · CIK 0001546216 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,780 F1 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2023. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000048 · wk-form4_1709673014.xml · derivative · entry 5 Goff Brian · CIK 0001546216 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,000 Underlying: Common stock · 8,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F5 · derivative.exercise_date: The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. F5 · derivative.expiration_date: The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 195,500 | $0.00 Strike: $32.27 | $0.00 |
DisclosureSEC source: 0001439222-24-000048 · wk-form4_1709673014.xml · derivative · entry 4 Goff Brian · CIK 0001546216 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 195,500 Underlying: Common stock · 195,500 shares Expires 2034-03-01 F4 · derivative.exercise_date: This option was granted on March 1, 2024. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2025, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 54,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000048 · wk-form4_1709673014.xml · derivative · entry 3 Goff Brian · CIK 0001546216 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,000 Underlying: Common stock · 54,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments. F3 · derivative.expiration_date: The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000048 · wk-form4_1709673014.xml · nonDerivative · entry 1 Goff Brian · CIK 0001546216 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,936 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 24, 2024 Filed Jan 24, 2024 21:20 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 7,635 | $21.64 | $165,221.40 |
DisclosureSEC source: 0001439222-24-000014 · wk-form4_1706131222.xml · nonDerivative · entry 2 Goff Brian · CIK 0001546216 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,436 F1 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated August 8, 2022. Read SEC document |
| January 20, 2024 Filed Jan 24, 2024 21:20 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionPerformance share units · Derivative | 17,018 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000014 · wk-form4_1706131222.xml · derivative · entry 3 Goff Brian · CIK 0001546216 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 102,110 Underlying: Common stock · 17,018 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The PSUs were granted on August 8, 2022. The PSUs vest as to 10% of the underlying shares upon the achievement of a specified research milestone and as to the remaining underlying shares upon the achievement of other clinical, research and regulatory milestones. The performance criteria for the specified research milestone was determined to have been met on January 20, 2024, resulting in the vesting of the PSUs as to 10% of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The PSUs were granted on August 8, 2022. The PSUs vest as to 10% of the underlying shares upon the achievement of a specified research milestone and as to the remaining underlying shares upon the achievement of other clinical, research and regulatory milestones. The performance criteria for the specified research milestone was determined to have been met on January 20, 2024, resulting in the vesting of the PSUs as to 10% of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| January 20, 2024 Filed Jan 24, 2024 21:20 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 17,018 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000014 · wk-form4_1706131222.xml · nonDerivative · entry 1 Goff Brian · CIK 0001546216 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 09, 2024 Filed Jan 9, 2024 21:28 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 12,066 | $22.99 | $277,397.34 |
DisclosureSEC source: 0001439222-24-000010 · wk-form4_1704835697.xml · nonDerivative · entry 2 Goff Brian · CIK 0001546216 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,053 F1 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated August 8, 2022. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:28 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionPerformance share units · Derivative | 25,527 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000010 · wk-form4_1704835697.xml · derivative · entry 3 Goff Brian · CIK 0001546216 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,128 Underlying: Common stock · 25,527 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The PSUs were granted on August 8, 2022. The PSUs vest as to 15% of the underlying shares upon the achievement of a specified clinical milestone and as to the remaining 85% of the underlying shares upon the achievement of other clinical, research and regulatory milestones. The performance criteria for the specified clinical milestone was determined to have been met on January 5, 2024, resulting in the vesting of the PSUs as to 15% of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The PSUs were granted on August 8, 2022. The PSUs vest as to 15% of the underlying shares upon the achievement of a specified clinical milestone and as to the remaining 85% of the underlying shares upon the achievement of other clinical, research and regulatory milestones. The performance criteria for the specified clinical milestone was determined to have been met on January 5, 2024, resulting in the vesting of the PSUs as to 15% of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 21:28 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 25,527 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000010 · wk-form4_1704835697.xml · nonDerivative · entry 1 Goff Brian · CIK 0001546216 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,119 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 20:07 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 22,691 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000123 · wk-form4_1691698025.xml · derivative · entry 3 Goff Brian · CIK 0001546216 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,382 Underlying: Common stock · 22,691 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on August 8, 2022. Beginning on August 8, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. F3 · derivative.expiration_date: The restricted stock units were granted on August 8, 2022. Beginning on August 8, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 20:07 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 10,178 | $25.48 | $259,335.44 |
DisclosureSEC source: 0001439222-23-000123 · wk-form4_1691698025.xml · nonDerivative · entry 2 Goff Brian · CIK 0001546216 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,592 F1 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 20:07 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 22,691 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000123 · wk-form4_1691698025.xml · nonDerivative · entry 1 Goff Brian · CIK 0001546216 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,770 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2023 Filed Jun 30, 2023 20:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | SaleCommon stock | 11,449 | $28.36 | $324,693.64 |
DisclosureSEC source: 0001439222-23-000103 · wk-form4_1688155500.xml · nonDerivative · entry 2 Goff Brian · CIK 0001546216 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,079 F1 · kind: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. Read SEC document |
| June 28, 2023 Filed Jun 30, 2023 20:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionPerformance share units · Derivative | 25,528 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000103 · wk-form4_1688155500.xml · derivative · entry 3 Goff Brian · CIK 0001546216 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 144,655 Underlying: Common stock · 25,528 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The PSUs vest as to 15% of the underlying shares upon the achievement of a specified clinical milestone and as to the remaining 85% of the underlying shares upon the achievement of other clinical, research and regulatory milestones. The performance criteria for the specified clinical milestone was determined to have been met on June 28, 2023, resulting in the vesting of the PSUs as to 15% of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The PSUs vest as to 15% of the underlying shares upon the achievement of a specified clinical milestone and as to the remaining 85% of the underlying shares upon the achievement of other clinical, research and regulatory milestones. The performance criteria for the specified clinical milestone was determined to have been met on June 28, 2023, resulting in the vesting of the PSUs as to 15% of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 28, 2023 Filed Jun 30, 2023 20:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 25,528 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000103 · wk-form4_1688155500.xml · nonDerivative · entry 1 Goff Brian · CIK 0001546216 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,528 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 94,500 | $0.00 Strike: $25.01 | $0.00 |
DisclosureSEC source: 0001439222-23-000048 · wf-form4_167787754123125.xml · derivative · entry 2 Goff Brian · CIK 0001546216 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,500 Underlying: Common stock · 94,500 shares Expires 2033-03-01 F3 · derivative.exercise_date: This option was granted on March 1, 2023. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 25,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000048 · wf-form4_167787754123125.xml · derivative · entry 1 Goff Brian · CIK 0001546216 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,500 Underlying: Common stock · 25,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| August 08, 2022 Filed Aug 9, 2022 20:50 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 68,073 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000074 · wf-form4_166007821499099.xml · derivative · entry 2 Goff Brian · CIK 0001546216 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,073 Underlying: Common stock · 68,073 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on August 8, 2022. Beginning on August 8, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. F3 · derivative.expiration_date: The restricted stock units were granted on August 8, 2022. Beginning on August 8, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| August 08, 2022 Filed Aug 9, 2022 20:50 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock option (right to buy) · Derivative | 561,083 | $0.00 Strike: $29.38 | $0.00 |
DisclosureSEC source: 0001439222-22-000074 · wf-form4_166007821499099.xml · derivative · entry 1 Goff Brian · CIK 0001546216 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 561,083 Underlying: Common stock · 561,083 shares Expires 2032-08-08 F1 · derivative.exercise_date: This option was granted on August 8, 2022. The shares underlying this option vest as to 25% of the underlying shares on August 8, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| July 21, 2021 Filed Jul 23, 2021 16:42 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Disposition to issuerOption to Purchase Common Stock · Derivative | 21,750 | $100.14 Strike: $100.14 | $2,178,045.00 |
DisclosureSEC source: 0000899866-21-000069 · wf-form4_162707291289703.xml · derivative · entry 2 Goff Brian · CIK 0001546216 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $.0001 per share · 21,750 shares Expires 2027-06-07 F2 · derivative.exercise_date: Upon the First Effective Time, these options were cancelled and converted into the right to receive the product obtained by multiplying (A) the excess, if any, of the value of the Merger Consideration over the exercise price per share of the Alexion common stock subject to such options immediately prior to the First Effective Time by (B) the number of shares of Alexion common stock subject to such option immediately prior to the First Effective Time by (ii) the value of the Merger Consideration. Read SEC document |
| July 21, 2021 Filed Jul 23, 2021 16:42 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Disposition to issuerCommon Stock, par value $.0001 per share | 150,832 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-21-000069 · wf-form4_162707291289703.xml · nonDerivative · entry 1 Goff Brian · CIK 0001546216 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration"). Read SEC document |
| July 14, 2021 Filed Jul 16, 2021 16:43 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 29,501 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-21-000051 · wf-form4_162646819566694.xml · nonDerivative · entry 2 Goff Brian · CIK 0001546216 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,832 F2 · shares: On July 14, 2021 the Leadership and Compensation Committee certified that certain performance metrics under previously granted performance stock units were satisfied. These performance stock units were previously granted in February 2020 under the 2017 Stock Incentive Plan. Read SEC document |
| July 14, 2021 Filed Jul 16, 2021 16:43 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 30,643 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-21-000051 · wf-form4_162646819566694.xml · nonDerivative · entry 1 Goff Brian · CIK 0001546216 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,331 F1 · shares: On July 14, 2021 the Leadership and Compensation Committee certified that certain performance metrics under previously granted performance stock units were satisfied. These performance stock units were previously granted in February 2019 under the 2017 Stock Incentive Plan. Read SEC document |
| June 08, 2021 Filed Jun 9, 2021 16:52 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Tax withholdingCommon Stock, par value $.0001 per share | 1,086 | $177.00 | $192,222.00 |
DisclosureSEC source: 0000899866-21-000049 · wf-form4_162327193288127.xml · nonDerivative · entry 1 Goff Brian · CIK 0001546216 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,688 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. Read SEC document |
| February 28, 2021 Filed Mar 2, 2021 17:55 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 24,473 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-21-000026 · wf-form4_161472574182653.xml · nonDerivative · entry 1 Goff Brian · CIK 0001546216 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,774 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. 25% vests on each anniversary of the grant date. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 17:09 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Tax withholdingCommon Stock, par value $.0001 per share | 3,261 | $157.96 | $515,107.56 |
DisclosureSEC source: 0000899866-20-000095 · wf-form4_160832936211224.xml · nonDerivative · entry 3 Goff Brian · CIK 0001546216 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,301 F3 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 17:09 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Tax withholdingCommon Stock, par value $.0001 per share | 18,134 | $157.96 | $2,864,446.64 |
DisclosureSEC source: 0000899866-20-000095 · wf-form4_160832936211224.xml · nonDerivative · entry 2 Goff Brian · CIK 0001546216 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,562 F2 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 17:09 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 40,677 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-20-000095 · wf-form4_160832936211224.xml · nonDerivative · entry 1 Goff Brian · CIK 0001546216 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,696 F1 · shares: Shares acquired on vesting of Performance Stock Units previously granted on February 28, 2018 under the 2017 Stock Incentive Plan. Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 16:58 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Tax withholdingCommon Stock, par value $.0001 per share | 1,642 | $114.61 | $188,189.62 |
DisclosureSEC source: 0000899866-20-000062 · wf-form4_159173630026912.xml · nonDerivative · entry 1 Goff Brian · CIK 0001546216 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,019 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 18:18 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Tax withholdingCommon Stock, par value $.0001 per share | 1,401 | $90.54 | $126,846.54 |
DisclosureSEC source: 0000899866-20-000019 · wf-form4_158327748870501.xml · nonDerivative · entry 2 Goff Brian · CIK 0001546216 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,661 F2 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $90.48 - $92.39. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 18:18 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 10,880 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-20-000019 · wf-form4_158327748870501.xml · nonDerivative · entry 1 Goff Brian · CIK 0001546216 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,062 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. 25% vests on each anniversary of the grant date. Read SEC document |
| February 07, 2020 Filed Feb 10, 2020 16:58 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Tax withholdingCommon Stock, par value $.0001 per share | 1,594 | $102.97 | $164,134.18 |
DisclosureSEC source: 0000899866-20-000015 · wf-form4_158137191608200.xml · nonDerivative · entry 1 Goff Brian · CIK 0001546216 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,182 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $102.97 - $103.24. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| June 07, 2019 Filed Jun 11, 2019 18:38 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Tax withholdingCommon Stock, par value $.0001 per share | 1,643 | $118.61 | $194,876.23 |
DisclosureSEC source: 0000899866-19-000076 · wf-form4_156029269946793.xml · nonDerivative · entry 1 Goff Brian · CIK 0001546216 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,776 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 17:36 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Tax withholdingCommon Stock, par value $.0001 per share | 670 | $132.93 | $89,063.10 |
DisclosureSEC source: 0000899866-19-000037 · wf-form4_155173898108036.xml · nonDerivative · entry 1 Goff Brian · CIK 0001546216 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,991 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $132.90- $134.96. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 20:19 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 9,428 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-19-000049 · wf-form4_155183517005730.xml · nonDerivative · entry 1 Goff Brian · CIK 0001546216 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,419 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. 25% vests on each anniversary of the grant date. Read SEC document |
| February 07, 2019 Filed Feb 11, 2019 18:20 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Tax withholdingCommon Stock, par value $.0001 per share | 1,596 | $119.57 | $190,833.72 |
DisclosureSEC source: 0000899866-19-000012 · wf-form4_154992720701029.xml · nonDerivative · entry 1 Goff Brian · CIK 0001546216 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,661 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $119.43 - $119.57. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 16:51 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 1,645 | $118.53 | $194,981.85 |
DisclosureSEC source: 0000899866-18-000102 · wf-form4_152883666838735.xml · nonDerivative · entry 1 Goff Brian · CIK 0001546216 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,257 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 17:00 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 8,940 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-18-000058 · wf-form4_152002798864307.xml · nonDerivative · entry 1 Goff Brian · CIK 0001546216 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,902 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. 25% vests on each anniversary of the grant date. Read SEC document |
| February 08, 2018 Filed Feb 8, 2018 19:17 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 1,651 | $116.31 | $192,027.81 |
DisclosureSEC source: 0000899866-18-000042 · wf-form4_151813545767461.xml · nonDerivative · entry 2 Goff Brian · CIK 0001546216 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,962 F2 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $116.00 - $116.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 19:17 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 15,894 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-18-000042 · wf-form4_151813545767461.xml · nonDerivative · entry 1 Goff Brian · CIK 0001546216 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,613 F1 · shares: On February 6, 2018, the Leadership and Compensation Committee determined that the reporting person earned 15,894 Performance Share Units upon achievement of certain performance targets previously established by the Committee. 1/3 of such shares vested on February 6, 2018 and 1/3 vest on each subsequent anniversary Read SEC document |
| June 07, 2017 Filed Jun 9, 2017 18:35 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantOption to Purchase Common Stock · Derivative | 21,750 | $100.14 Strike: $100.14 | $2,178,045.00 |
DisclosureSEC source: 0000899866-17-000136 · wf-form4_149704771327359.xml · derivative · entry 2 Goff Brian · CIK 0001546216 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,750 Underlying: Common Stock, par value $.0001 per share · 21,750 shares Expires 2027-06-07 F2 · shares: Award of Stock Options under the 2017 Incentive Plan. 25% vest on the 1-year anniversary of the grant date, and 1/16 vest every 90 days thereafter. Read SEC document |
| June 07, 2017 Filed Jun 9, 2017 18:35 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 14,719 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-17-000136 · wf-form4_149704771327359.xml · nonDerivative · entry 1 Goff Brian · CIK 0001546216 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,719 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. 25% vest on each anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.